AF
BBIO icon

Allworth Financial’s BridgeBio Pharma BBIO Stock Holding History

Allworth Financial’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.7K Buy
412
+95
+30% +$6.65K ﹤0.01% 2874
2026
Q1 		$23.5K Buy
317
+26
+9% +$1.89K ﹤0.01% 2873
2025
Q4 		$22.3K Sell
291
-26
-8% -$1.71K ﹤0.01% 2748
2025
Q3 		$16.5K Buy
317
+101
+47% +$4.93K ﹤0.01% 2826
2025
Q2 		$9.33K Buy
216
+16
+8% +$582 ﹤0.01% 2922
2025
Q1 		$7.19K Buy
200
+68
+52% +$2.29K ﹤0.01% 2583
2024
Q4 		$4.73K Buy
132
+5
+4% +$129 ﹤0.01% 2791
2024
Q3 		$3.23K Hold
127
– – ﹤0.01% 2758
2024
Q2 		$3.33K Sell
127
-9
-7% -$246 ﹤0.01% 2699
2024
Q1 		$4.21K Sell
136
-62
-31% -$2.11K ﹤0.01% 2481
2023
Q4 		$7.99K Buy
198
+71
+56% +$2.13K ﹤0.01% 2067
2023
Q3 		$3.35K Hold
127
– – ﹤0.01% 2308
2023
Q2 		$2.19K Hold
127
– – ﹤0.01% 2448
2023
Q1 		$2.11K Buy
127
+109
+606% +$1.27K ﹤0.01% 2384
2022
Q4 		$137 Sell
18
-50
-74% -$479 ﹤0.01% 2880
2022
Q3 		$1K Buy
+68
New +$706 ﹤0.01% 2312
2022
Q1 		– Sell
-354
Closed -$6K – 2114
2021
Q4 		$6K Buy
+354
New +$15K ﹤0.01% 1509

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Allworth Financial's BBIO Position: Q2 2026 in Review

Allworth Financial increased its BridgeBio Pharma (BBIO) stake by 30% in Q2 2026, buying an estimated $6.65K and bringing the position to 412 shares worth $30.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

Allworth Financial first reported a position in BBIO in Q4 2021 and has held it in 17 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Allworth Financial held 412 shares of BridgeBio Pharma worth $30.7K as of Q2 2026.
  • Allworth Financial bought 95 BridgeBio Pharma shares in Q2 2026, an estimated $6.65K.
  • BridgeBio Pharma made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2874 holding.
  • Allworth Financial first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 17 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.